Rhopressa for Glaucoma
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.
Will I have to stop taking my current medications?
If you are currently taking IOP-lowering medications, you must be willing to stop them to participate in this trial. There is a required washout period (time without taking certain medications) before starting the study.
Is Rhopressa (netarsudil) safe for humans?
How is the drug Rhopressa unique for treating glaucoma?
Rhopressa (netarsudil) is unique because it lowers eye pressure by increasing fluid outflow through the eye's natural drainage system, the trabecular meshwork, using a once-daily evening dose. This mechanism is different from many other glaucoma treatments, which often reduce fluid production or increase outflow through alternative pathways.12356
What data supports the effectiveness of the drug Rhopressa (netarsudil) for treating glaucoma?
Research shows that Rhopressa (netarsudil) effectively lowers eye pressure in people with open-angle glaucoma or high eye pressure, with studies indicating it works as well as another common treatment, timolol. It helps by improving fluid drainage in the eye, and most side effects are mild, like eye redness.12357
Are You a Good Fit for This Trial?
This trial is for adults over 18 with primary open-angle glaucoma or ocular hypertension who've had SLT surgery in the last 90 days. They should have an IOP of 16-28 mmHg and could benefit from further IOP reduction. Women must use birth control if capable of pregnancy. Exclusions include more than one SLT treatment, prior MIGS, current rho kinase inhibitor use, advanced glaucoma, unreliable tonometry readings, active eye infections or inflammation, retinal disease, recent investigational drug/device involvement.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Rhopressa or placebo for IOP reduction post-SLT
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Netarsudil ophthalmic solution 0.02%
Find a Clinic Near You
Who Is Running the Clinical Trial?
East Coast Institute for Research
Lead Sponsor
Alcon, a Novartis Company
Industry Sponsor
Florida Eye Specialists
Collaborator